Home > Healthcare > Pharmaceuticals > Finished Drug Form > Pigmentation Disorder Treatment Market

Pigmentation Disorder Treatment Market Size

  • Report ID: GMI8528
  • Published Date: Mar 2024
  • Report Format: PDF

Pigmentation Disorder Treatment Market Size

Pigmentation Disorder Treatment Market size was valued at USD 7.1 billion in 2023 and is expected to reach USD 11.6 billion by 2032, growing at a CAGR of 5.8% over the analysis period. The increasing prevalence of pigmentation disorder, such as vitiligo, melasma, post-inflammatory hyperpigmentation, coupled with growing awareness among the population is driving the market expansion.


For instance, according to a research article published in the Karger Journal in 2021, individuals with dark skin exhibit a notably high prevalence of pigmentary disorders. The pigmentary disorders rank as the 3rd and 4th most common dermatoses worldwide. Therefore, the high prevalence of pigmentation disorders is anticipated to generate opportunities for market expansion globally.


Pigmentation disorder treatment encompasses a range of medical interventions and procedures designed to address and rectify irregularities in skin pigmentation. These conditions result in alterations of skin, hair, or eye coloration due to changes in the production or distribution of melanin, a pigment responsible for determining skin color. The disorders may include vitiligo, melasma, post-inflammatory hyperpigmentation, albinism, and similar conditions.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global pigmentation disorders treatment market was valued at USD 7.1 billion in 2023 and is expected to reach USD 11.6 billion by 2032, backed by the increasing prevalence of pigmentation disorders, such as vitiligo, melasma, and post-inflammatory hyperpigmentation among others.

The drugs segment accounted USD 4 billion in 2023 and will record notable demand through 2032, owing to increased R&D activities and product launches by major players in the industry.

In 2023, North America pigmentation disorders treatment market share was around 42.2%, and is expected to show impressive growth through 2032, attributed to high healthcare expenditure, alongside advanced medical infrastructure in the region.

AbbVie Inc., Candela Corporation, Cipher Pharmaceuticals Inc., Galderma, GlaxoSmithKline (GSK), Incyte, L'Oréal Paris, Novartis AG, Pfizer Inc., Pierre Fabre Group, and Shiseido Company Limited among others.

Pigmentation Disorder Treatment Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 192
  • Countries covered: 19
  • Pages: 125
 Download Free Sample